Johnson & Johnson Reports Positive PAPILLON Trial Results for Amivantamab in Lung Cancer

Johnson & Johnson today announced positive results from the Phase 3 PAPILLON trial evaluating amivantamab plus carboplatin-pemetrexed chemotherapy in patients with EGFR exon 20 insertion-mutated non-small cell lung cancer. The trial met its primary endpoint, demonstrating a significant improvement in progression-free survival compared to chemotherapy alone.